Early reperfusion strategies after acute ST-segment elevation myocardial infarction: the importance of timing
Author:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 2 (1) , 22-28
Abstract
Acute ST-segment elevation myocardial infarction is estimated to occur in more than 500,000 people in the US every year. With the introduction of reperfusion therapy by fibrinolysis or primary angioplasty, mortality has significantly fallen. Although fibrinolysis is more readily available than primary angioplasty, the latter is more effective and results in better short-term and long-term outcomes if performed in a timely manner by an experienced operator and hospital team. The ischemic time, door-to-balloon time and clinical risk are important determinants of favorable outcome. Primary angioplasty is the preferred reperfusion strategy when symptom onset is longer than 3 h, in high-risk patients, such as those with cardiogenic shock, congestive heart failure or elderly age, and those with contraindications for fibrinolysis. Primary angioplasty is the preferred strategy in interventional facilities, with a goal door-to-balloon time of less than 90 min. For patients who present to noninterventional facilities, transfer to a hospital capable of primary angioplasty is safe and effective if the additional treatment delay is less than 90 min. Facilitated percutaneous coronary intervention has been shown in several small trials to offer early vessel patency and improve outcomes compared with fibrinolysis alone, but has not been shown to reduce mortality. Larger trials are ongoing to evaluate the benefit of this approach. The establishment of an effective and efficient system for the rapid transport of patients to centers capable and experienced in primary angioplasty is severely needed to provide optimum treatment and outcomes to patients with ST-segment elevation acute myocardial infarction.Keywords
This publication has 41 references indexed in Scilit:
- Mortality Benefit of Immediate Revascularization of Acute ST-Segment Elevation Myocardial Infarction in Patients With Contraindications to Thrombolytic TherapyJAMA, 2003
- Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital SettingCirculation, 2003
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised studyThe Lancet, 2002
- Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace.The American Journal of Cardiology, 2002
- Evaluation of the time saved byprehospital initiation of reteplase forST-elevation myocardial infarctionJACC, 2002
- Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial InfarctionCirculation, 2002
- Clinical characteristics and outcome of patients with early (4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionEuropean Heart Journal, 2002
- Mortality and Prehospital Thrombolysis for Acute Myocardial InfarctionJAMA, 2000
- Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial InfarctionNew England Journal of Medicine, 1997